XML 33 R21.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation	6 Months Ended
Stock-Based Compensation	Jun. 30, 2025
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	Stock-Based Compensation The Human Resources and Compensation Committee of our Board of Directors granted 3,680,476 RSUs and 1,702,363 performance-based restricted stock units (“PSUs”) to our employees during the first six months of 2025 under our Omnibus Equity Incentive Plan. Our electing non-employee directors received 297,901 deferred share units (“DSUs”) and 953,332 deferred RSUs (“DRSUs”) during the six months ended June 30, 2025 under our Omnibus Equity Incentive Plan. We measure the fair value of grants of RSUs, DSUs and DRSUs based on the closing market price of a share of our common stock on the date of the grant (or if the market is not open for trading on such date, the immediately preceding day on which the market is open for trading). The weighted average fair value per share was $1.19 for RSUs granted to employees and $0.92 and $0.71, respectively, for DSUs and DRSUs granted to non-employee directors during the six months ended June 30, 2025. We measure the fair value of grants of PSUs using a Monte Carlo valuation. The weighted average fair value of the PSUs granted in the first six months of 2025 was $0.61 per share and will be expensed over a vesting period of three years. The final payout to holders of PSUs will be based upon the Company’s total shareholder return relative to a peer group’s performance measured at the end of each performance period. The final payout for PSUs granted in 2025 is subject to a 3.5x value cap. In the three months ended June 30, 2025 and 2024, we recognized $1.8 million and $1.6 million, respectively, of stock-based compensation expense. The majority of the expense, $1.6 million and $1.4 million, respectively, was recorded in selling and administrative expense in the Condensed Consolidated Statements of Operations, with the remaining expense recorded in cost of goods sold. In the six months ended June 30, 2025 and 2024, we recognized $2.4 million and $2.6 million, respectively, of stock-based compensation expense. The majority of the expense, $1.9 million and $2.2 million, respectively, was recorded in selling and administrative expense in the Condensed Consolidated Statements of Operations, with the remaining expense recorded in cost of goods sold. As of June 30, 2025, the unrecognized compensation cost related to the unvested portion of all stock-based awards was approximately $10.8 million and is expected to be recognized over the remaining vesting period of the respective grants.